Accueil>>Signaling Pathways>> PROTAC>> Ligand for E3 Ligase>>Lenalidomide-OH

Lenalidomide-OH

Catalog No.GC60223

Le lénalidomide-OH est un analogue du ligand céréblon (CRBN) lénalidomide pour l'ubiquitine ligase E3, et est utilisé dans le recrutement de la protéine CRBN. Le lénalidomide-OH peut être connecté au ligand de la protéine par un lieur pour former des PROTAC, tels que le dégradeur PROTAC BTK SJF620.

Products are for research use only. Not for human use. We do not sell to patients.

Lenalidomide-OH Chemical Structure

Cas No.: 1416990-08-3

Taille Prix Stock Qté
100mg
122,00 $US
En stock
500mg
365,00 $US
En stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Avis des clients

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Lenalidomide-OH is an analog of cereblon (CRBN) ligand Lenalidomide for E3 ubiquitin ligase, and is used in the recruitment of CRBN protein. Lenalidomide-OH can be connected to the ligand for protein by a linker to form PROTACs, such as the PROTAC BTK degrader SJF620 [1].

Lenalidomide-OH can be connected to the ligand for protein by a linker to form PROTACs. PROTACs are inducers of ubiquitination-mediated degradation of cancer-promoting proteins[1].

[1]. Jaime-Figueroa S, et al. Design, synthesis and biological evaluation of Proteolysis Targeting Chimeras (PROTACs) as a BTK degraders with improved pharmacokinetic properties. 2020 Feb 1;30(3):126877.

Avis

Review for Lenalidomide-OH

Average Rating: 5 ★★★★★ (Based on Reviews and 38 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Lenalidomide-OH

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.